Event-free survival of patients with genotypes based on common FLT3-ITD and NPM1 gene mutations. Control remission induction therapy versus clofarabine combination treatment. The favorable effect of the clofarabine regimen on EFS and OS (OS not shown) is evident in the comparatively larger molecular subset of AML of intermediate prognostic risk¹²  with nonmutated nucleophosmin-1 (NPM1) gene and absence of FLT3-ITD (Fms-like tyrosine kinase without internal tandem gene duplications) (n = 68 vs 67; EFS, 18% ± 5 vs 40% ± 7, Cox P < .001; OS, 22% ± 6 vs 49% ± 8, P < .001).